|1.||Sultana, Sarwat: 6 articles (09/2015 - 01/2006)|
|2.||Yao, Deng-Fu: 5 articles (09/2013 - 12/2007)|
|3.||Yao, Min: 4 articles (06/2014 - 04/2010)|
|4.||Wu, Wei: 4 articles (06/2011 - 12/2007)|
|5.||Qiu, Li-Wei: 4 articles (06/2011 - 12/2007)|
|6.||van Steeg, H: 3 articles (04/2011 - 01/2001)|
|7.||de Vries, Annemieke: 3 articles (08/2007 - 08/2004)|
|8.||Hoogervorst, Esther M: 3 articles (08/2007 - 08/2004)|
|9.||van Steeg, Harry: 3 articles (08/2007 - 08/2004)|
|10.||Hasan, Syed Kazim: 2 articles (09/2015 - 07/2013)|
07/01/2001 - "Thus, VD3 appears to be effective in suppressing liver-specific early chromosomal as well as DNA damage during the process of rat hepatocarcinogenesis initiated with 2-AAF and promoted by STZ contributing to its promise as a cancer chemotherapeutic agent."
10/01/1979 - "Addition of 4 ppm Se to the drinking water of male albino rats fed diets containing 0.03% 2-acetylaminofluorene (AAF) provided protection against hepatic damage and also resulted in at least 50% reduction in liver tumor incidence. "
06/17/2011 - "In the present study, we investigated the underlying events associated with tumor-promoting activity of 2-acetylaminofluorene (2-AAF), a powerful complete genotoxic rat liver carcinogen. "
08/01/2004 - "p53 heterozygosity had no influence on liver tumor incidences, in line with the results obtained from the short-term 2-AAF studies revealing no altered cellular response in p53(+/-) or Xpa/p53(+/-) mice. "
07/01/2004 - "Fumonisin B1-induced hepatocellular and cholangiocellular tumors in male Fischer 344 rats: potentiating effects of 2-acetylaminofluorene on oval cell proliferation and neoplastic development in a discontinued feeding study."
|2.||Hepatocellular Carcinoma (Hepatoma)
03/27/2002 - "In this study, we report that 2-AAF could also activate the human MDR1 gene in human hepatoma and embryonic fibroblast 293 cells. "
06/01/2014 - "A rodent hepatoma model was established by feeding N-2-fluorenylacetamide (2-N-FAA) to male Sprague-Dawley rats. "
09/28/2013 - "Hepatoma models were made by inducing with 2-fluorenylacetamide (2-FAA) on male Sprague-Dawley rats. "
08/01/2008 - "Hepatoma models were induced by 2-fluorenylacetamide (2-FAA) in male Sprague-Dawley rats. "
12/01/2007 - "A rat model of hepatoma induced with 2-fluorenylacetamide (2-FAA, 0.05%) was established in male Sprague-Dawley rats. "
|3.||Liver Neoplasms (Liver Cancer)
01/01/1980 - "The incidence of bladder and liver neoplasms developed in mice continuously fed 2-acetylaminofluorene (2-AAF) in a multidisciplined study conducted at the National Center for Toxicological Research (NCTR) is represented using a probit model. "
06/02/2001 - "In addition, we have demonstrated that Xpc mutant mice are highly predisposed to the induction of lung and liver cancers by treatment with 2-acetylaminofluorene (2-AAF) and N-OH-2-AAF. "
05/01/1988 - "For the in vivo assay, male F344 rats were first exposed to N-2-fluorenylacetamide (FAA) for 8 weeks to induce liver altered foci, after which those maintained on control diet for an additional 12 weeks developed a 33% incidence of liver neoplasms. "
04/01/1982 - "This difference in thyroid activity might take an important part in the mechanism responsible for the sex difference in liver cancer induction by N-2-fluorenylacetamide."
01/01/1980 - "Finally, the response of liver neoplasms to 2-AAF is represented in the dose time plane using a probit plane model. "
|4.||Body Weight (Weight, Body)
02/01/1992 - "Two diets used widely in toxicological and/or nutritional studies, and considered to be nutritionally adequate, were compared with respect to their influence on growth, body weight, lifespan, spontaneous neoplasia, and neoplastic responses to 2-acetylaminofluorene (2-AAF). "
12/01/1983 - "The relationships between the shelf level at which mice were housed and body weight and food consumption/wastage were examined by analyzing data obtained from the first 9 months of a carcinogenic dose-response study carried out in 24,192 female BALB/c mice using 2-acetylaminofluorene (2-AAF) as the carcinogen. "
01/01/2013 - "Extracts of doses of 100 mg/kg body weight were given to rats in five groups for seven consecutive days followed by a single dose of 2-AAF (0.5 mmol/kg body weight). "
11/01/1998 - "Eight-week-old GST-P-Tg and N-Tg rats were administered DEN intraperitoneally at 100 mg/kg body weight, subjected to a selection procedure with 2-acetylaminofluorene and CCl4, and killed at the end of weeks 5 and 12. "
01/11/1990 - "O6-alkylguanine-DNA-alkyltransferase (ATase) activity was increased in rat liver from 80 to 320 fmoles/mg total protein 48 h after administration of 2-acetylaminofluorene at 60 mg/kg body weight. "
|5.||Urinary Bladder Neoplasms (Bladder Cancer)
01/01/1980 - "Induction of bladder neoplasms was shown to occur early in the study, but was dependent upon the continuous presence of 2-AAF. "
08/01/2007 - "An analysis of differentially expressed genes in non-tumorigenic tissue and bladder tumors of p53.S389A after long-term exposure to 2-AAF revealed 319 genes. "
07/01/1991 - "Bladder tumors occurred only at the highest 2-AAF dose in female mice. "
07/01/1991 - "For this purpose, the dose response of formation of hepatocellular and bladder tumors after 30 mo of feeding 2-acetylaminofluorene (2-AAF) in the diet was assessed in 4 F1 mouse hybrids, including the B6C3F1 hybrid. "
05/01/1991 - "Female BALB/c mice continuously fed 2-acetylaminofluorene (AAF) develop liver and bladder tumors. "
|2.||Proliferating Cell Nuclear Antigen (PCNA)
|4.||Carboxymethylcellulose Sodium (Polycell)
|8.||Caffeine (No Doz)